Learn More
The designation employed and the presentation of the material in this report including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization and the Ecumenical Pharmaceutical Network concerning the legal status of any country, territory, city or area or of authorities or concerning the(More)
BACKGROUND The quality of medicines available in some less-developed countries is inadequate in terms of content of active ingredient. Reasons for the poor quality of drugs include widespread counterfeiting of medicines in less-developed countries, excessive decomposition of active ingredient as a result of high temperature and humidity, and poor quality(More)
The designation employed and the presentation of the material in this report including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization and the International Pharmaceutical Federation concerning the legal status of any country, territory, city or area or of authorities or concerning the(More)
Rapid proliferation in small cell lung cancer (SCLC) may be mediated by synthesis of autocrine growth factors. Bombesin (or its mammalian homologue gastrin releasing peptide, GRP) may have autocrine function in SCLC (Cuttitta et al., 1985; Carney et al., 1987) but is not synthesised by the faster growing variant SCLC lines (Carney et al., 1985).(More)
We have detected somatostatin receptors (SSR) by autoradiography in 3/4 established small cell lung cancer (SCLC) cell lines but not in two non-SCLC cell lines. The growth of 1/3 SSR positive SCLC cell lines was significantly inhibited by the long-acting somatostatin analogue octreotide (SMS 201-995, Sandostatin) 10(-9) M. We treated 20 SCLC patients with(More)
A total of 53 women with chemotherapy-naïve stage Ic-IV ovarian cancer were treated with four cycles of carboplatin area under the curve 7 every 3 weeks, followed by four cycles of paclitaxel 70 mg m(-2) (days 1, 8, and 15) and gemcitabine 1000 mg m(-2) (days 1 and 8) every 3 weeks. In all, 37 (70%) had stage III/IV disease, with 22 (42%) having tumour >2(More)
Disclaimer Whereas this is an interagency publication, each agency implements activities in accordance with its mandate. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of PATH, the World Health Organization (WHO), or the United Nations Population Fund(More)
SCLC cell lines exhibit considerable heterogeneity as regards morphology, biochemistry and growth kinetics (Carney et al., 1985a). 'Classic' SCLC lines commonly grow as floating aggregates (morphology type I or II) and possess neuro-secretory granules (NSG) on electron microscopy. They express four biomarkers: creatine kinase-BB (CK-BB), neurone specific(More)
Analogues of the neurotransmitter substance P (SP) can interact with neuropeptide receptors, and are reported to inhibit growth of small cell lung cancer cell lines (SCLC CLs). We found [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P (D-Phe5SP) significantly inhibited DNA synthesis by 10/10 human tumour CLs; six SCLC, one N-SCLC (squamous), two ovarian and(More)